This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Formula Pharmaceuticals, Inc.
Drug Names(s): FPI-01, WT-1-vaccine
Description: FPI-01 is a unique, first-in-class, synthetic, multi-peptide immunotherapeutic that targets Wilm’s Tumor 1 (WT-1) antigen, a highly validated target for cancer immunotherapy. The lead indication for FPI-01 is acute myeloid leukemia (AML) in first-remission.
WT-1 is over-expressed (by up to 93% of patients) in many blood cancers and solid tumors, including AML, acute lymphocytic leukemia (ALL), mesothelioma, and cancers of the ovary, lung, breast and prostate. WT-1 was originally described as a tumor suppressor gene but it also appears to be involved in tumor formation and growth, as suggested by its up-regulation in these tumor types.
Deal Structure: Formula licensed FPI-01 on an exclusive worldwide basis from Memorial Sloan Kettering Cancer Center (MSKCC).
Additional information available to subscribers only: